US2018335423A1PendingUtilityA1

Methods for Detecting Symmetrical Dimethylarginine

Assignee: IDEXX LAB INCPriority: Aug 7, 2008Filed: May 11, 2018Published: Nov 22, 2018
Est. expiryAug 7, 2028(~2 yrs left)· nominal 20-yr term from priority
C07C 279/12G01N 33/6812C07K 16/44A61P 13/12G01N 33/53G01N 33/54366
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Method of detecting Symmetrical dimethyl arginine (SDMA) in biological samples. SDMA analogs for generating anti-SDMA antibodies having little or no cross-reactivity with asymmetrical dimethyl arginine, arginine, and monomethylarginine. The analogs have a protected or free thiol (—SH) group or hydroxyl (—OH) group that allow them to be linked to a suitable conjugation target which can be, for example, a protein containing molecule of a label. The anti-SDMA antibodies can be used in diagnostic immunoassay for the diagnosis of SDMA associated disorders and/or diseases.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . A device for determining the presence of free symmetrical dimethylarginine (SDMA) in a sample, the device comprising a solid phase having immobilized thereon free SDMA from the sample. 
     
     
         2 . The device of  claim 1 , further having immobilized thereon an SDMA analog conjugated to a label. 
     
     
         3 . A test device having immobilized thereon free SDMA from a patient sample. 
     
     
         4 . The test device of  claim 3 , further having immobilized thereon an SDMA analog conjugated to a label. 
     
     
         5 . A method for detecting the presence or amount of free symmetrical dimethylarginine (SDMA) in a sample, the method comprising:
 (a) contacting a device comprising a solid phase with a patient sample and with an SDMA analog conjugated to a label;   (b) immobilizing the free SDMA from the sample to the solid phase;   (c) immobilizing the SDMA analog to the solid phase; and   (d) detecting the presence or amount of the SDMA analog immobilized to the solid phase, thereby determining the presence or amount of free SDMA in the sample.   
     
     
         6 . A method for determining the presence of free symmetrical dimethylarginine (SDMA) in a patient sample, the method comprising specifically binding the free SDMA from the sample onto a solid phase, wherein the presence of the SDMA on the solid phase indicates the presence of free SDMA in the sample.

Join the waitlist — get patent alerts

Track US2018335423A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.